0001570562-23-000117.txt : 20231208 0001570562-23-000117.hdr.sgml : 20231208 20231208181559 ACCESSION NUMBER: 0001570562-23-000117 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231206 FILED AS OF DATE: 20231208 DATE AS OF CHANGE: 20231208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MOATAZEDI DAVID CENTRAL INDEX KEY: 0001700836 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38381 FILM NUMBER: 231476591 MAIL ADDRESS: STREET 1: C/O OBALON THERAPEUTICS, INC. STREET 2: 5421 AVENIDA ENCINAS, SUITE F CITY: CARLSBAD STATE: CA ZIP: 92008 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Evolus, Inc. CENTRAL INDEX KEY: 0001570562 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461385614 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 520 NEWPORT CENTER DRIVE STREET 2: SUITE 1200 CITY: NEWPORT BEACH STATE: CA ZIP: 92660 BUSINESS PHONE: (949) 284-4555 MAIL ADDRESS: STREET 1: 520 NEWPORT CENTER DRIVE STREET 2: SUITE 1200 CITY: NEWPORT BEACH STATE: CA ZIP: 92660 4 1 wk-form4_1702077349.xml FORM 4 X0508 4 2023-12-06 0 0001570562 Evolus, Inc. EOLS 0001700836 MOATAZEDI DAVID 520 NEWPORT CENTER DR. SUITE 1200 NEWPORT BEACH CA 92660 1 1 0 0 See Remarks 0 Common Stock 2023-12-06 4 S 0 51348 10.0859 D 635244 D Common Stock 2023-12-08 4 S 0 31300 9.7286 D 603944 D The shares were sold in multiple trades at prices ranging from $10.00 to $10.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The shares were sold in multiple trades at prices ranging from $9.61 to $9.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. President and Chief Executive Officer /s/ Jeffrey J. Plumer, as attorney-in-fact for David Moatazedi 2023-12-08